Y mAbs Therapeutics (YMAB)

NASDAQ
Currency in USD
Disclaimer
5.16
-0.03
(-0.58%)
Real-time Data
Day's Range
5.01
5.16
52 wk Range
2.70
15.89
Volume
12,674
Prev. Close
5.19
Open
5.12
Day's Range
5.01-5.16
52 wk Range
2.7-15.89
Volume
12,674
Average Volume (3m)
206,024
1-Year Change
-64.57%
Shares Outstanding
43,620,192
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
12.00
Upside +132.56%

People Also Watch

6.890
EPM
+0.58%
2.810
GSIT
-3.77%
50.25
IMCR
+1.52%
10.330
SOI
-0.48%
How do you feel today about YMAB?
Vote to see community's results!
or
  • 5 Huge Analyst Calls

Y mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel, antibody-based therapeutic cancer products. The Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. Its product pipeline includes DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and one product candidate at the registration-stage, OMBLASTYS (omburtamab), which targets tumors that express B7-H3. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb) that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. Omburtamab is a novel murine monoclonal antibody designed for compartmental immunotherapy. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several types of cancers, including pediatric CNS/LM from NB.

Income Statement